Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.
Ankelien DuchowJudith Bellmann-StroblTim FriedeOrhan AktasKlemens AngstwurmIlya AyzenbergAchim BertheleEva DawinDaniel EngelsKatinka FischerMartina FlaskampKatrin GiglhuberMatthias GrotheJoachim HavlaMartin W HümmertSven JariusMatthias KastePeter KernIngo KleiterLuisa KlotzMirjam Korporal-KuhnkeMarkus KraemerMarkus KrumbholzTania KümpfelLisa LohmannMarius RingelsteinPaulus RommerPatrick SchindlerCharlotte SchubertCarolin SchwakeMakbule SenelFlorian Then BerghDaria TkachenkoHayrettin TumamiCorinna TrebstIoannis VardakasAnnette WalterClemens WarnkeMartin S WeberJonathan WickelBrigitte WildemannAlexander WinkelmannFriedemann PaulJan-Patrick StellmannVivien Häußlernull nullPublished in: Annals of neurology (2023)
NMOSD and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. This article is protected by copyright. All rights reserved.